journal article·2018-07-04Open access

Superiority of amino-modified chiral mesoporous silica nanoparticles in delivering indometacin

Jing Li, Yingyu Guo, Heran Li, Lei Shang, Sanming Li

Abstract

The present study established indometacin (IMC) delivery system with chiral mesoporous silica nanoparticles (CMSNs) and amino-modified chiral mesoporous silica nanoparticles (Amino-CMSNs) that previously reported as pharmaceutical excipients, and their systemic biological effects, mainly consisting of in vitro drug intestinal permeability, haemolysis assay, in vivo pharmacokinetics, anti-inflammation pharmacodynamics and gastric irritation, were addressed. It turned out that the two IMC delivery systems established by CMSN and Amino-CMSN significantly improved drug intestinal permeability due to the improved drug dissolution caused by conversion of drug crystalline state to amorphous phase. Further, IMC-loaded Amino-CMSN was the superior choice because of its higher dissolution rate. Furthermore, CMSN and Amino-CMSN were safe to be circulated in blood, and Amino-CMSN with significant lower haemolysis ratio than CMSN was better for the minimum haemolytic behaviour. Oral bioavailability and anti-inflammation effect of IMC delivery systems established by CMSN and Amino-CMSN were enhanced compared with IMC, which was attributed to the primary cause of the improvement of IMC dissolution, and Amino-CMSN exhibited better biological effect. As a result of these facts, it is believed that the effective delivery of IMC by Amino-CMSN will provide a new candidate to formulate poorly soluble drugs so as to significantly develop pharmaceutical application.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Mesoporous Materials and Catalysis · Analytical Chemistry and Chromatography · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Wuya College of Innovation, Shenyang Pharmaceutical University

School of Pharmacy, Shenyang Pharmaceutical University

College of basic medical sciences, Shenyang medical college

References (49)

Show source-provided references
1. 10.1016/j.colsurfb.2013.04.00910.1016/j.colsurfb.2013.04.009 ↗
2. 10.1016/j.colsurfb.2016.02.00910.1016/j.colsurfb.2016.02.009 ↗
3. 10.1016/j.msec.2015.05.03910.1016/j.msec.2015.05.039 ↗
4. 10.1016/j.msec.2015.09.09110.1016/j.msec.2015.09.091 ↗
5. 10.1002/adma.20110476310.1002/adma.201104763 ↗
6. 10.1016/j.addr.2012.07.01810.1016/j.addr.2012.07.018 ↗
7. 10.1039/c0jm03851b10.1039/c0jm03851b ↗
8. 10.1080/21691401.2017.129064810.1080/21691401.2017.1290648 ↗
9. 10.1039/C2CS35297D10.1039/C2CS35297D ↗
10. 10.1038/nature0252910.1038/nature02529 ↗
11. 10.1016/j.materresbull.2014.11.03010.1016/j.materresbull.2014.11.030 ↗
12. 10.1021/cm06110710.1021/cm061107 ↗
13. 10.1002/adma.20060270310.1002/adma.200602703 ↗
14. 10.1002/adfm.20080063110.1002/adfm.200800631 ↗
15. 10.1039/C0CS00002G10.1039/C0CS00002G ↗
16. 10.1002/chem.20110214610.1002/chem.201102146 ↗
17. 10.1016/j.addr.2008.03.01210.1016/j.addr.2008.03.012 ↗
18. 10.1039/a704156j10.1039/a704156j ↗
19. 10.1002/adfm.20040062210.1002/adfm.200400622 ↗
20. 10.1002/adma.20030632310.1002/adma.200306323 ↗
21. 10.1021/ja026855o10.1021/ja026855o ↗
22. 10.1016/j.ejpb.2007.05.01010.1016/j.ejpb.2007.05.010 ↗
23. 10.1016/j.addr.2007.05.01410.1016/j.addr.2007.05.014 ↗
24. TanejaShilpi S, Khatri SK. Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement. Artif Cell Nanomed Biotechnol. 2016;44:978–984.
25. 10.3109/21691401.2015.101226110.3109/21691401.2015.1012261 ↗
26. 10.1016/j.ejpb.2005.05.00910.1016/j.ejpb.2005.05.009 ↗
27. 10.1016/S0169-409X(00)00118-610.1016/S0169-409X(00)00118-6 ↗
28. 10.3109/10731199.2010.51625910.3109/10731199.2010.516259 ↗
29. 10.1080/21691401.2016.118572610.1080/21691401.2016.1185726 ↗
30. 10.1016/j.addr.2007.05.00310.1016/j.addr.2007.05.003 ↗
31. 10.1016/j.jcis.2011.07.02210.1016/j.jcis.2011.07.022 ↗
32. 10.1016/j.ejpb.2011.07.00110.1016/j.ejpb.2011.07.001 ↗
33. 10.1016/j.micromeso.2011.06.00110.1016/j.micromeso.2011.06.001 ↗
34. 10.1016/j.ijpharm.2015.07.01410.1016/j.ijpharm.2015.07.014 ↗
35. 10.1016/j.micromeso.2012.12.03710.1016/j.micromeso.2012.12.037 ↗
36. 10.1016/j.msec.2013.08.01410.1016/j.msec.2013.08.014 ↗
37. 10.1016/j.ijpharm.2012.09.00810.1016/j.ijpharm.2012.09.008 ↗
38. 10.3109/02713683.2010.53629410.3109/02713683.2010.536294 ↗
39. 10.3109/0265204090324344510.3109/02652040903243445 ↗
40. 10.1021/acs.molpharmaceut.6b0102310.1021/acs.molpharmaceut.6b01023 ↗
41. 10.1021/acs.molpharmaceut.6b0080310.1021/acs.molpharmaceut.6b00803 ↗
42. 10.1021/acs.molpharmaceut.5b0029910.1021/acs.molpharmaceut.5b00299 ↗
43. 10.1021/acs.molpharmaceut.5b0085310.1021/acs.molpharmaceut.5b00853 ↗
44. 10.1080/21691401.2016.127692410.1080/21691401.2016.1276924 ↗
45. 10.1080/21691401.2016.120226210.1080/21691401.2016.1202262 ↗
46. 10.1016/S0142-9612(99)00148-910.1016/S0142-9612(99)00148-9 ↗
47. 10.1021/ja064594310.1021/ja0645943 ↗
48. 10.1016/j.ejps.2015.02.00810.1016/j.ejps.2015.02.008 ↗
49. 10.1016/j.ejpb.2011.12.00210.1016/j.ejpb.2011.12.002 ↗